Geode Capital Management LLC Buys 259,010 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Geode Capital Management LLC boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,700,782 shares of the company's stock after acquiring an additional 259,010 shares during the quarter. Geode Capital Management LLC owned 2.17% of Vaxcyte worth $308,675,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Riverview Trust Co bought a new position in shares of Vaxcyte during the 3rd quarter worth approximately $27,000. Fifth Third Bancorp bought a new position in Vaxcyte in the second quarter valued at $35,000. Blue Trust Inc. grew its position in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. Quest Partners LLC acquired a new stake in Vaxcyte in the 2nd quarter valued at $70,000. Finally, Meeder Asset Management Inc. lifted its position in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after buying an additional 635 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the company's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $92.25, for a total value of $218,263.50. Following the transaction, the chief executive officer now directly owns 136,215 shares of the company's stock, valued at $12,565,833.75. This represents a 1.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction on Monday, October 7th. The stock was sold at an average price of $109.27, for a total value of $546,350.00. Following the sale, the senior vice president now directly owns 28,623 shares of the company's stock, valued at $3,127,635.21. This represents a 14.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 117,830 shares of company stock worth $12,600,310. 3.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Bank of America raised their price objective on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. BTIG Research boosted their price target on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Leerink Partners increased their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a report on Tuesday, September 3rd. Jefferies Financial Group raised their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Finally, Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Stock Down 0.2 %

Shares of NASDAQ PCVX traded down $0.15 during midday trading on Friday, hitting $87.72. 977,015 shares of the company's stock were exchanged, compared to its average volume of 904,422. The firm has a market capitalization of $10.93 billion, a PE ratio of -19.07 and a beta of 0.94. Vaxcyte, Inc. has a 12 month low of $53.83 and a 12 month high of $121.06. The company's 50 day moving average price is $101.11 and its 200 day moving average price is $91.85.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the company posted ($0.91) EPS. On average, equities research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.